HedgePath Pharmaceuticals Announces Positive FDA Feedback from FDA Type-C Meeting and Files Pre-NDA Meeting Request

Author's Avatar
Aug 06, 2018
Article's Main Image

FDA has confirmed HPPI's clinical and regulatory pathway for SUBA BCCNS and provided further guidance for anticipated NDA submission

PR Newswire